Pharmacological preconditioning with erythropoietin reduces ischemia-reperfusion injury in the small intestine of rats

Aims: Considering the implications that arose from several recent experimental studies using recombinant human erythropoietin in rodents, erythropoietin has been regarded as a pharmacological preconditioning agent. The purpose of the present study was to evaluate whether erythropoietin has a preconditioning effect against ischemia and reperfusion injury in the small intestine of the rat. Main methods: Intestinal ischemia was induced in male Wistar rats by clamping the superior mesenteric artery for 30 min, followed by reperfusion for 180 min. Recombinant human erythropoietin (1000 or 3000 U/kg) or vehicle was administered intraperitoneally 24 h prior to ischemia. After collection of ileal tissue, evaluation of damage was based on measurements of the accumulation of polymorphonuclear neutrophils by technetium-99m-labeled leukocyte uptake, content of malondialdehyde, reduced glutathione, contractile responses to agonists, and an evaluation of histopathological features in intestinal tissue. Key findings: Treatment with erythropoietin 24 h before ischemia significantly reduced the tissue content of malondialdehyde and increased that of reduced glutathione. Pretreatment also significantly suppressed leukocyte infiltration into the postischemic tissue, as evidenced by the lower content of myeloperoxidase and technetium-99m-labeled leukocytes. Physiological and histopathological improvements were also significant with the rHuEpo treatment. Significance: Results of the present study indicate that rHuEpo is an effective preconditioning agent in ischemic injury of the small intestine. Protection provided by recombinant human erythropoietin is closely related to the inhibition of oxidative stress and leukocyte infiltration, which might be among the possible protective mechanisms of erythropoietin in intestinal ischemia and reperfusion. © 2009 Elsevier Inc. All rights reserved.

Dergi Adı Life Sciences
Dergi Cilt Bilgisi 84
Dergi Sayısı 11.Dec
Sayfalar 364 - 371
Yayın Yılı 2009
Eser Adı
[dc.title]
Pharmacological preconditioning with erythropoietin reduces ischemia-reperfusion injury in the small intestine of rats
Yazar
[dc.contributor.author]
Sayan, Hale
Yazar
[dc.contributor.author]
Özaçmak, Veysel Haktan
Yazar
[dc.contributor.author]
Şen, Feyza
Yazar
[dc.contributor.author]
Çabuk, Mehmet
Yazar
[dc.contributor.author]
Atik-Yörük, Duygu
Yazar
[dc.contributor.author]
Akyıldız-İğdem, Ayşenur
Yazar
[dc.contributor.author]
Özaçmak, I. Diler
Yayın Yılı
[dc.date.issued]
2009
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Aims: Considering the implications that arose from several recent experimental studies using recombinant human erythropoietin in rodents, erythropoietin has been regarded as a pharmacological preconditioning agent. The purpose of the present study was to evaluate whether erythropoietin has a preconditioning effect against ischemia and reperfusion injury in the small intestine of the rat. Main methods: Intestinal ischemia was induced in male Wistar rats by clamping the superior mesenteric artery for 30 min, followed by reperfusion for 180 min. Recombinant human erythropoietin (1000 or 3000 U/kg) or vehicle was administered intraperitoneally 24 h prior to ischemia. After collection of ileal tissue, evaluation of damage was based on measurements of the accumulation of polymorphonuclear neutrophils by technetium-99m-labeled leukocyte uptake, content of malondialdehyde, reduced glutathione, contractile responses to agonists, and an evaluation of histopathological features in intestinal tissue. Key findings: Treatment with erythropoietin 24 h before ischemia significantly reduced the tissue content of malondialdehyde and increased that of reduced glutathione. Pretreatment also significantly suppressed leukocyte infiltration into the postischemic tissue, as evidenced by the lower content of myeloperoxidase and technetium-99m-labeled leukocytes. Physiological and histopathological improvements were also significant with the rHuEpo treatment. Significance: Results of the present study indicate that rHuEpo is an effective preconditioning agent in ischemic injury of the small intestine. Protection provided by recombinant human erythropoietin is closely related to the inhibition of oxidative stress and leukocyte infiltration, which might be among the possible protective mechanisms of erythropoietin in intestinal ischemia and reperfusion. © 2009 Elsevier Inc. All rights reserved.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Erythropoietin
Konu Başlıkları
[dc.subject]
Intestinal ischemia
Konu Başlıkları
[dc.subject]
Oxidative stress
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0024-3205
İlk Sayfa Sayısı
[dc.identifier.startpage]
364
Son Sayfa Sayısı
[dc.identifier.endpage]
371
Dergi Adı
[dc.relation.journal]
Life Sciences
Dergi Sayısı
[dc.identifier.issue]
11.Dec
Dergi Cilt Bilgisi
[dc.identifier.volume]
84
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1016/j.lfs.2008.12.025
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/6992
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
53
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
09 Şubat 2024 08:11
Google Kontrol
Tıklayınız
erythropoietin ischemia tissue leukocyte preconditioning content reduced reperfusion intestine injury evaluation rHuEpo infiltration significantly intestinal technetium-99m-labeled malondialdehyde glutathione histopathological present recombinant mechanisms suppressed Pretreatment increased possible protective before closely Treatment findings Elsevier features rights reserved
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms